Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
Stopped Early discontinuation based on strategic sponsor decision not driven by any safety concerns
Conditions
Interventions
- BIOLOGICAL: SAR444200
- BIOLOGICAL: Atezolizumab
Sponsor
Sanofi